The joint venture facility, which covers 87,120 square feet and is co-owned through XHemplar S.R.L, now has a perimeter security fence being erected as well as and a comprehensive CCTV security system that is expected to be completed imminently.
CROP and XHemplar are currently working with Italian agencies to import new and unique, high CBD genetics to populate its upgraded facility that are expected to command premium prices. Discussions are also continuing with an Italy-based pharmaceutical company to secure off-take agreements for the 2019 harvests.
In addition, CROP and XHemplar have identified six potential retail locations throughout Italy and are in negotiations to open two of the retail locations shortly. It is also planned to build a state-of-the-art extraction facility that would add significant value by allowing for in-house processing of hemp biomass.
CROP Infrastructure CEO, Michael Yorke, stated: “Italy is our bridgehead into Europe. Our Italian partners are making significant progress on multiple fronts to ensure that the European operations are running at full capacity to take full advantage of the rapidly growing demand there.
“Our unique, high CBD strains, will position CROP as a low-cost and high-quality pure CBD provider, both domestically in North America, and throughout the European market. The joint venture’s CBD products will be branded under the XHemplar and CROP brands Tiffany CBD and Hempire Italia.”
Cannabis industry analysts, The Brightfield Group, estimates the hemp-CBD market alone could hit $22 billion by 2022.
Crop is publicly listed on the CSE and trades under the symbol “CROP” and in the US under the symbol “CRXPF”. CROP is focused on cannabis branding and real estate assets. The Company’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada Cannabis farm, 2,115 acres of CBD farms, extraction in Nevada and joint ventures on West Hollywood and San Bernardino dispensary apps with international focuses in Jamaica and Italy.
CROP has developed a portfolio of assets including Canna Drink, a cannabis infused functional beverage line, US and Italian distribution rights to over 55 cannabis topical products and a portfolio of 16 Cannabis brands. CROP’s infrastructure has over 150,000 sq ft of built canopy and over 2,900 acres of real estate.
Disclaimer for Forward-Looking Information
Certain statements in this press release are forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. In addition, marijuana remains a Schedule I drug under the United States Controlled Substances Act of 1970. Although Congress has prohibited the US Justice Department from spending federal funds to interfere with the implementation of state medical marijuana laws, this prohibition must be renewed each year to remain in effect. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the expected returns from the Italy Project; the technological effects of Italy Project; the intention to expand its portfolio; and execute on its business plan. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding the regulatory and legal framework regarding the cannabis industry in general among all levels of government and zoning; risks associated with applicable securities laws and stock exchange rules relating to the cannabis industry; risks associated with maintaining its interests in its various assets; the ability of the Company to finance operations and execute its business plan and other factors beyond the control of the Company. Such forward-looking statements should therefore be construed in light of such factors, and the Company is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
The CSE has not reviewed, approved or disapproved the content of this press release.
Michael Yorke – CEO and Director